1. |
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health. Lancet, 2018, 391(10131): 1706-1717.
|
2. |
Garvey C, Criner GJ. Impact of comorbidities on the treatment of chronic obstructive pulmonary disease. Am J Med, 2018, 131(9): 23-29.
|
3. |
王新安, 刘鲜艳, 欧阳修河. 慢性阻塞性肺疾病合并骨质疏松症研究进展. 中国呼吸与危重监护杂志, 2017, 16(6): 627-630.
|
4. |
Yohannes AM, Kaplan A, Hanania NA. Anxiety and depression in chronic obstructive pulmonary disease: Recognition and management. Clev Clin J Med, 2018, 85(2 Suppl 1): S11-S18.
|
5. |
韩萍, 姜文青, 殷彬, 等. COPD合并抑郁症的研究进展. 中国卫生产业, 2016, 13(6): 196-198.
|
6. |
Regvat J, Mitek A, Vegnuti M, et al. Anxiety and depression during hospital treatment of exacerbation of chronic obstructive pulmonary disease. J Int Med Res, 2011, 39(3): 1028-1038.
|
7. |
Montserrat-Capdevila J, Godoy P, Marsal JR, et al. Mental disorders in chronic obstructive pulmonary diseases. Perspect Psychiatr C, 2018, 54(3): 398-404.
|
8. |
Atlantis E, Fahey P, Cochrane B, et al. Bidirectional associations between clinically relevant depression or anxiety and COPD: A systematic review and meta-analysis. Chest, 2013, 144(3): 766-777.
|
9. |
文富强. 重视慢性阻塞性肺疾病的合并症. 中华肺部疾病杂志(电子版), 2013, 6(2): 99-102.
|
10. |
Pelgrim CE, Peterson JD, Gosker HR, et al. Psychological co-morbidities in COPD: targeting systemic inflammation, a benefit for both?. Eur J Pharmacol, 2019, 842: 99-110.
|
11. |
Zilz C, Blaas SH, Pfeifer M, et al. Mental health, serum biomarkers and survival in severe COPD: a pilot study. Multidiscip Respir Med, 2015, 11: 3.
|
12. |
Pumar MI, Gray CR, Walsh JR, et al. Anxiety and depression-Important psychological comorbidities of COPD. J Thorac Dis, 2014, 6(11): 1615-1631.
|
13. |
Al-shair K, Kolsum U, Dockry R, et al. Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. Respir Res, 2011, 12: 3.
|
14. |
Xu W, Collet J, Shapiro S, et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Resp Crit Care, 2008, 178(9): 913-920.
|
15. |
Usmani ZA, Carson KV, Heslop K, et al. Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease. Cochrane Db Syst Rev, 2017, 9(3): D10673.
|
16. |
Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res, 2017, 18(1): 67.
|
17. |
Xiao T, Qiu H, Chen Y, et al. Prevalence of anxiety and depression symptoms and their associated factors in mild COPD patients from community settings, Shanghai, China: a cross-sectional study. BMC Psychiatry, 2018, 18(1): 89.
|
18. |
Lou P, Zhu Y, Chen P, et al. Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study. BMC Pulm Med, 2012, 12(1): 53.
|
19. |
Varol Y, Anar C, Çimen P, et al. Sex-related differences in COPD Assessment Test scores of COPD populations with or without significant anxiety and/or depression. Turk J Med SCI, 2017, 47(1): 61-68.
|
20. |
Zhang H, Wang X, Lin J, et al. Grey and white matter abnormalities in chronic obstructive pulmonary disease: a case-control study. BMJ Open, 2012, 2(2): e844.
|
21. |
Johnson PL, Samuels BC, Fitz SD, et al. Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia. Neuropsychopharmacol, 2012, 37(8): 1911-1922.
|
22. |
文富强, 陈磊. GOLD 2017 更新与中国慢阻肺临床实践. 西部医学, 2018, (1): 1-2.
|
23. |
Brook A, Zhang C. The role of personal attributes in the genesis and progression of lung disease and cigarette smoking. Am J Public Health, 2013, 103(5): 931-937.
|
24. |
Sundar IK, Yao H, Huang Y, et al. Serotonin and corticosterone rhythms in mice exposed to cigarette smoke and in patients with COPD: implication for COPD-associated neuropathogenesis. PLoS One, 2014, 9(2): e87999.
|
25. |
Ghaderi A, Nasehghafoori P, Rasouli-Azad M, et al. Examining of thallium in cigarette smokers. Biol Trace Elem Res, 2018, 182(2): 224-230.
|
26. |
Altemus M, Sarvaiya N, Neill Epperson C. Sex differences in anxiety and depression clinical perspectives. Front Neuroendocrin, 2014, 35(3): 320-330.
|
27. |
Zhang Q, Liao J, Liao X, et al. Disease knowledge level is a noteworthy risk factor of anxiety and depression in patients with chronic obstructive pulmonary disease: a cross-sectional study. BMC Pulm Med, 2014, 14(1): 92.
|
28. |
Yu T, Ter Riet G, Puhan MA, et al. Physical activity and risk of comorbidities in patients with chronic obstructive pulmonary disease: a cohort study. NPJ Prim Care Respir Med, 2017, 27(1): 36.
|
29. |
Hyun MK, Lee NR, Jang EJ, et al. Effect of inhaled drugs on anxiety and depression in patients with chronic obstructive pulmonary disease: a prospective observational study. Int J Chron Obstruct Pulmon Dis, 2016, 11(1): 747-754.
|
30. |
Jácome C, Figueiredo D, Gabriel R, et al. Predicting anxiety and depression among family carers of people with chronic obstructive pulmonary disease. Int Psychogeriatr, 2014, 26(7): 1191-1199.
|
31. |
Mi E, Mi E, Ewing G, et al. Associations between the psychological health of patients and carers in advanced COPD. Int J Chronic Obstruct Obst Dis, 2017, 12: 2813-2821.
|
32. |
中华医学会神经病学分会神经心理学与行为神经病学组. 综合医院焦虑、抑郁与躯体化症状诊断治疗的专家共识. 中华神经科杂志, 2016, 49(12): 908-917.
|
33. |
Vanfleteren LEGW, Spruit MA, Wouters EFM, et al. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med, 2016, 4(11): 911-924.
|
34. |
Yawn B, Kim V. COPD in primary care: Key considerations for optimized management: Treatment options for stable chronic obstructive pulmonary disease: Current recommendations and unmet needs. J Fam Pract, 2018, 67(2 Suppl): S28-S37.
|
35. |
Schuler M, Strohmayer M, Muhlig S, et al. Assessment of depression before and after inpatient rehabilitation in COPD patients: psychometric properties of the German version of the Patient Health Questionnaire (PHQ-9/PHQ-2). J Affect Disord, 2018, 232: 268-275.
|
36. |
Livermore N, Dimitri A, Sharpe L, et al. Cognitive behaviour therapy reduces dyspnoea ratings in patients with chronic obstructive pulmonary disease (COPD). Respir Physiol Neurobiol, 2015, 216: 35-42.
|
37. |
姚文飞, 屠春林, 赵开顺, 等. 慢性阻塞性肺疾病的肺康复研究进展. 临床肺科杂志, 2017, 22(2): 347-350.
|
38. |
da Silva GP, Nascimento FA, Macêdo TP, et al. Religious coping and religiosity in patients with COPD following pulmonary rehabilitation. Int J Chronic Obstruct Obst Dis, 2018, 13: 175-181.
|
39. |
Wang L, Mårtensson J, Zhao Y, et al. Experiences of a health coaching self-management program in patients with COPD: a qualitative content analysis. Int J Chron Obstruct Pulmon Dis, 2018, 13: 1527-1536.
|
40. |
He Y, Zheng Y, Xu C, et al. Sertraline hydrochloride treatment for patients with stable chronic obstructive pulmonary disease complicated with depression: a randomized controlled trial. Clin Respir J, 2016, 10(3): 318-325.
|
41. |
Rosa F, Bagnasco A, Ghirotto L, et al. Experiences of older people following an acute exacerbation of chronic obstructive pulmonary disease: a phenomenological study. J Clin Nurs, 2018, 27(5-6): e1110-e1119.
|